Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.
Researchers assessed diabetic macular edema risk among adults using one of three classes of diabetes medication as well as adults using multiple classes of medication in a retrospective study published in Journal of Diabetes and Its Complications. None of the medications were associated with higher risk for diabetic macular edema, though adults who had a higher HbA1c and a shorter duration of